MedTrace Logo

The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

NCT01667406 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2021-06-08

Study results available
· View outcomes & findings →

Summary

We want to find out if kisspeptin is successful in stimulating oocyte maturation when it is used as a 'trigger' injection during IVF therapy for infertility.

Conditions

Interventions

DRUG

Kisspeptin 1.6nmol/kg

single kisspeptin dose 1.6 nmol/kg subcutaneously

DRUG

Kisspeptin 3.2nmol/kg

single kisspeptin dose 3.2 nmol/kg subcutaneously

DRUG

Kisspeptin 6.4nmol/kg

single kisspeptin dose 6.4 nmol/kg subcutaneously

DRUG

Kisspeptin 9.6nmol/kg

single kisspeptin dose 9.6 nmol/kg subcutaneously

DRUG

Kisspeptin 12.8nmol/kg

single kisspeptin dose 12.8 nmol/kg subcutaneously

DRUG

Kisspeptin 9.6 nmol/kg double

kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously

DRUG

Kisspeptin 9.6 nmol/kg + saline

kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Waljit S Dhillo, PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-01
Primary Completion
2016-10-11
Completion
2016-10-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667406 on ClinicalTrials.gov